Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations
Abstract
Among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), the use of potent P2Y12 inhibitor (e.g., prasugrel or ticagrelor) is associated with a reduction in ischemic events as well as an increase in bleeding events compared with clopidogrel treatment. Therefore, finding an optimal balance between the efficacy and safety of antiplatelet strategies after PCI (i.e., optimal disease entity, regimen, potency, and duration) has been one of the challenging projects.
Recently, the main issue in this field has shifted toward reducing serious bleeding without increasing ischemic risk. Thereafter, numerous clinical trials have evaluated clinical benefits of the de-escalation antiplatelet strategies compared with the conventional strategy.